FDB (First Databank, Inc.)

We’re thrilled to announce our Keynote Speaker for the FDB Customer Conference. Prepare to be transformed as Stephen Trzeciak, MD, a renowned physician scientist and co-author of "Compassionomics: The Revolutionary Scientific Evidence that Caring Makes a Difference," takes the stage and addresses the current compassion crisis in healthcare.   His groundbreaking research demonstrates the substantial impact of compassion on patient outcomes, healthcare provider well-being, and overall healthcare costs. Dr. Trzeciak will explore compelling evidence and share powerful stories showing that compassion is much more than a soft skill—it's a vital element of healthcare that can lead to life-changing outcomes. He will highlight how just 40 seconds of compassionate interaction can make a life-or-death difference.   Plan to join us October 9-11, 2024 at the Omni Austin Hotel in Austin, Texas!   Learn more and register for the conference: https://bit.ly/456RbuC | #FDBCustomers #ImprovedOutcomes #PatientOutcomes #MedicationDecisionSupport #DrugKnowledge

A non-profit representing cancer centers has published its latest biannual survey on the current state of cancer drug supplies—and it paints a complicated picture of shortages and the health of the supply chain.   “Most [cancer centers surveyed] are still managing shortages for more than one type of medication right now. These shortages not only put a burden on patients, caregivers, and providers, but they could also delay vital clinical trials and slow the pace of progress for new cancer therapies,” Crystal Denlinger, MD, Chief Executive Officer, National Comprehensive Cancer Network® (NCCN®), said in a statement.   Chad Van Alstin has the story for Health Exec: https://bit.ly/4cN3YVr | #HealthcareSupplyChain #DrugShortages #PtSafety #DrugKnowledge #CancerTreatment

Elimu Informatics proudly announces the publication of "PillHarmonics: An Orchestrated Pharmacogenetics Medication Clinical Decision Support Service" in Applied Clinical Informatics. PillHarmonics is a cutting-edge cloud-based CDS service that integrates with EHRs, merging data from FDB (First Databank, Inc.), PharmGKB, and local content to deliver a holistic view of medication interactions. This service reduces patient safety concerns and clinician burden by providing unified medication assessments. Elimu’s vision for precision medicine involves leveraging this growing data set for advanced clinical decision-making and ensuring timely updates as genomic knowledge evolves. Our consulting services and products, supported by our robust R&D track record, can help you implement FHIR-based strategies in precision medicine. Read the full article here: https://lnkd.in/emcCz8fx Visit our website to learn more about our services. Together, let's ease clinician burden and enhance patient safety: https://lnkd.in/eMigh_5a Find more of our publications here: https://lnkd.in/eWPsA9vz #HealthcareInnovation #Pharmacogenomics #ClinicalDecisionSupport #PrecisionMedicine #EHRIntegration #PatientSafety #FHIRStrategies #ResearchandDevelopment #SMARTonFHIR #FHIR  #HealthcareInformatics #ElimuInformatics #Elimu #AWSPartner #Innovation #HealthcareTechnology

As tempting as it might be to go for the cheaper alternatives on the market—or simply just to get your hands on a GLP-1 drug—the experts recommend steering clear.   “Consumers should purchase medications from state-licensed pharmacies or FDA-registered outsourcing facilities to minimize the risk of counterfeit products,” says Simona Dorf, PharmD, BCMAS, and clinical pharmacist at FDB. “It’s essential to verify prescriptions from licensed health care providers and avoid drugs recommended by unverified online sources or social media influencers.”   Read the full story from Amanda Loudin via Fortune: https://bit.ly/4cOmSey | #GLP1 #DrugKnowledge #DrugSafety #MedSafety

Eli Lilly’s Kisunla is now FDA approved for treating patients in the early stages of Alzheimer’s disease. In addition to slowing cognitive decline and disease progression, clinical trial results showed that amyloid beta plaques were reduced to the point where some patients could stop taking the infused therapy.   “This milestone will not only catalyze the next generation of therapies but also reframe how we deliver treatments,” Howard Fillit, MD, co-founder and chief science officer of the Alzheimer's Drug Discovery Foundation, said in a prepared statement. “It’s promising to see that some patients essentially enter remission, where they achieve full amyloid clearance with no resurgence in substantial plaque buildup for several years to follow.”   Read more from Frank Vinluan via MedCity News: https://bit.ly/4eNnfYO | #Kisunla #AlzheimersDisease #AmyloidBetaPlaques

Wishing you a safe and Happy #FourthOfJuly from FDB! #HappyFourth #JulyFourth

AI won’t fulfill its promise to transform American medicine if it isn’t appropriately integrated, step by step, across U.S. healthcare. This evolutionary process will have to be coaxed along with high levels of methodological rigor, risk awareness and nimble adaptability—not just from the government but from all interested parties. This conviction comes through between the lines of a recent blog post authored by Troy Tazbaz, director of the FDA’s Digital Health Center of Excellence (DHCoE).   “DHCoE wants to foster responsible AI innovations in healthcare while ensuring these technologies, when intended for use as medical devices, are safe and effective for the end-users, including patients. Additionally, we seek to foster a collaborative approach and alignment within the healthcare ecosystem around AI in healthcare.”   Dave Pearson has the story for AI in Healthcare: https://bit.ly/3RL88oC | #AIinHealthcare #AIGuardrails #AI

The Coalition for Health AI (CHAI) is seeking public comment on a draft framework for the responsible use of artificial intelligence in healthcare.    “We reached an important milestone today with the open and public release of our draft assurance standards guide and reporting tools,” said Brian Anderson, MD, CHAI’s first CEO, in a statement. “This step will demonstrate that a consensus-based approach across the health ecosystem can both support innovation in healthcare and build trust that AI can serve all of us.”   David Raths has the story for Healthcare Innovation: https://bit.ly/45JqrQR | #AIinHealthcare #HealthTech #AIGuardrails

The recent approval of Moderna’s respiratory syncytial virus (RSV) vaccine mRNA-1345 (mRESVIA) could encourage the use of mRNA technology across different landscapes.   "The RSV market landscape has witnessed substantial change in recent years owing to the emergence of novel vaccines and monoclonal antibodies for prophylaxis, and the approval of mRESVIA now represents another important addition," said Anaelle Tannen, infectious disease analyst at GlobalData Plc, in a news release. "The improved options for RSV prophylaxis will benefit physicians by providing more choice and tailoring vaccine administration for the individual."   Kennedy Ferruggia has the story for Pharmacy Times: https://bit.ly/45JVM5Z | #mRNAVaccines #Vaccines #HealthTechnology #FDAApprovals #DrugDevelopment MJH Life Sciences®

With all of the new and exciting implementations of AI, it is no surprise that it will be the number one most talked about topic over the next 12 months. But what will be the second most talked about topic?   In search of an answer to this question, Healthcare IT Today reached out to some experts during HIMSS 24. Virginia Halsey, Senior VP of Product Management at FDB offered her insights. “I really have to say if I’m honest, 2, 3, 4, and 5 are all AI. There are subcategories of AI because you can talk about budgets, you can talk about whether people are recovering in their budgets (some are, some aren’t), and you can talk about interoperability but really it’s about AI and it’s the subcategories.”   Grayson Miller brings us the story for Healthcare IT Today: https://bit.ly/3xKNnmh | #AIinHealthcare #AI #Interoperability #ClinicalWorkflows #HIMSS24